Please assess the completion status of the following clinical trial:

Trial Title: A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent prior to initiation of any study-mandated procedure.~2. Patients with symptomatic PAH in WHO Functional Class (FC) II or III.~3. Patients with PAH belonging to one of the following subgroups of the Dana Point Clinical Classification Group 1:~   1. Idiopathic, or,~  2. Heritable, or,~  3. Drug or toxin induced, or,~  4. Associated with one of the following:~   i. Connective tissue disease, ii. Congenital heart disease with simple systemic-to-pulmonary shunt at least 1 year after surgical repair, iii. HIV infection.~4. Documented hemodynamic diagnosis of PAH by right heart catheterization - performed at any time prior to Screening showing:~   1. Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg and,~  2. Resting pulmonary vascular resitance (PVR) \> 240 dyn.s.cm-5 and,~  3. Pulmonary capillary wede pressure (PCWP) or left ventricular end diastolic pressure (LVEDP) ≤ 15 mmHg.~5. 6-minute walk distance (6MWD) ≥ 150 m at Screening.~6. Able to fluently speak and read the local language.~7. Men or women aged 18-80; women of childbearing potential (as defined below) must:~   1. Have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline and agree to perform monthly serum pregnancy tests, and,~  2. Agree to use two reliable methods of contraception in parallel, from Screening Visit 1 until 1 month after study drug discontinuation (see details below).~      * A female is considered to have childbearing potential unless she meets at least one of the following criteria:~        * Previous bilateral salpingo and/or oophorectomy, or hysterectomy.~       * Premature ovarian failure confirmed by a specialist.~       * Pre-pubescence, XY genotype, Turner syndrome, uterine agenesis.~       * Postmenopausal, defined as 12 consecutive months with no menses without an alternative medical cause.~     * Of the two contraceptive methods that must be used, one must be from Group 1, and one must be from Group 2, defined as follows:~        * Group 1: Oral, implantable, transdermal or injectable hormonal contraceptives, intrauterine devices, female sterilization (tubal ligation or non surgical sterilization, e.g., permanent contraception with Essure procedure), or partner's sterilization (vasectomy). If a hormonal contraceptive is chosen from this group, it must be taken for at least 1 month prior to enrollment. Alternatively, if the Essure procedure is chosen as a contraceptive method, a hysterosalpingogram must have been performed to confirm correct location of the microinserts and tubal occlusion (as per manufacturer's recommendations).~       * Group 2: Female or male condoms, diaphragm or cervical cap, any of them in combination with a spermicide.~     * Sexual abstinence, rhythm methods, or contraception by the partner alone are not considered as acceptable methods of contraception for this study.~Exclusion Criteria:~1. Known moderate-to-severe obstructive lung disease (i.e., forced expiratory volume in one second \[FEV1\] \< 80 % of predicted, with FEV1 / forced vital capacity \[FVC\] \< 70%) or known significant chronic lung disease diagnosed by chest imaging (e.g., interstitial lung disease, emphysema).~2. Known moderate-to-severe restrictive lung disease (i.e., total lung capacity \[TLC\] \< 60% of predicted value).~3. Hemoglobin \< 100g/L at Screening.~4. Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 3 X upper limit of the normal range (ULN) at Screening.~5. Patients undergoing dialysis.~6. Systolic blood pressure (SBP) \< 90 mmHg at Screening.~7. Body weight \< 40 kg at Screening.~8. Known concomitant life-threatening diseases with a life expectancy of \< 12 months.~9. Treatment with ERAs within 3 months prior to Visit 2, or scheduled to receive any of these compounds, other than macitentan, during the trial.~10. Treatment with intravenous or subcutaneous prostacyclin or prostacyclin analogs within 3 months prior to Visit 2, or scheduled to receive any of these compounds during the trial.~11. Treatment with soluble guanylate cyclase stimulator (riociguat) within 3 months prior to Visit 2, or scheduled to receive riociguat during the trial.~12. Patients who changed the dose of or discontinued phosphodiesterase type-5 inhibitor (PDE5i), inhaled prostacyclin analogues, or calcium channel blockers within 3 months prior to Visit 2.~13. Initiation of diuretics within 1 week prior to the Baseline period.~14. Patients on oral diuretics in whom the dose has not been stable for at least 1 week prior to the Baseline period.~15. Treatment with cytochrome P4500 (CYP) 3A inducers within 4 weeks prior to Visit 2.~16. Recently started (\< 8 weeks prior to Visit 2) or planned cardio-pulmonary rehabilitation program based on exercise.~17. Females who are lactating or pregnant (positive Screening or Baseline pregnancy test) or plan to become pregnant during the study.~18. Known hypersensitivity to macitentan or its excipients or drugs of the same class.~19. Treatment with another investigational drug within 3 months prior to Visit 2.~20. Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Macitentan (Type: EXPERIMENTAL): Macitentan tablet, dose of 10 mg, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).